TY - JOUR
T1 - Current Applications of Artificial Intelligence in Benign Prostatic Hyperplasia
AU - Shah, Milap
AU - Naik, Nithesh
AU - Hameed, BM Zeeshan
AU - Paul, Rahul
AU - Shetty, Dasharathraj K.
AU - Ibrahim, Sufyan
AU - Rai, Bhavan Prasad
AU - Chlosta, Piotr
AU - Rice, Patrick
AU - Somani, Bhaskar K.
N1 - Funding Information:
Funding: The authors declared that this study has received no financial support.
Publisher Copyright:
@ Author(s).
PY - 2022/7
Y1 - 2022/7
N2 - Artificial intelligence is used in predicting the clinical outcomes before minimally invasive treatments for benign prostatic hyperplasia, to address the insufficient reliability despite multiple assessment parameters, such as flow rates and symptom scores. Various models of artificial intelligence and its contemporary applications in benign prostatic hyperplasia are reviewed and discussed. A search strategy adapted to identify and review the literature on the application of artificial intelligence with a dedicated search string with the following keywords: “Machine Learning,” “Artificial Intelligence,” AND “Benign Prostate Enlargement” OR “BPH” OR “Benign Prostatic Hyperplasia” was included and categorized. Review articles, editorial comments, and non-urologic studies were excluded. In the present review, 1600 patients were included from 4 studies that used different classifiers such as fuzzy systems, computer-based vision systems, and clinical data mining to study the applications of artificial intelligence in diagnoses and severity prediction and determine clinical factors responsible for treatment response in benign prostatic hyperplasia. The accuracy to correctly diagnose benign prostatic hyperplasia by Fuzzy systems was 90%, while that of computer-based vision system was 96.3%. Data mining achieved sensitivity and specificity of 70% and 50%, respectively, in correctly predicting the clinical response to medical treatment in benign prostatic hyperplasia. Artificial intelligence is gaining attraction in urology, with the potential to improve diagnostics and patient care. The results of artificial intelligence-based applications in benign prostatic hyperplasia are promising but lack generaliz-ability of results. However, in the future, we will see a shift in the clinical paradigm as artificial intelligence applications will find their place in the guidelines and revolutionize the decision-making process.
AB - Artificial intelligence is used in predicting the clinical outcomes before minimally invasive treatments for benign prostatic hyperplasia, to address the insufficient reliability despite multiple assessment parameters, such as flow rates and symptom scores. Various models of artificial intelligence and its contemporary applications in benign prostatic hyperplasia are reviewed and discussed. A search strategy adapted to identify and review the literature on the application of artificial intelligence with a dedicated search string with the following keywords: “Machine Learning,” “Artificial Intelligence,” AND “Benign Prostate Enlargement” OR “BPH” OR “Benign Prostatic Hyperplasia” was included and categorized. Review articles, editorial comments, and non-urologic studies were excluded. In the present review, 1600 patients were included from 4 studies that used different classifiers such as fuzzy systems, computer-based vision systems, and clinical data mining to study the applications of artificial intelligence in diagnoses and severity prediction and determine clinical factors responsible for treatment response in benign prostatic hyperplasia. The accuracy to correctly diagnose benign prostatic hyperplasia by Fuzzy systems was 90%, while that of computer-based vision system was 96.3%. Data mining achieved sensitivity and specificity of 70% and 50%, respectively, in correctly predicting the clinical response to medical treatment in benign prostatic hyperplasia. Artificial intelligence is gaining attraction in urology, with the potential to improve diagnostics and patient care. The results of artificial intelligence-based applications in benign prostatic hyperplasia are promising but lack generaliz-ability of results. However, in the future, we will see a shift in the clinical paradigm as artificial intelligence applications will find their place in the guidelines and revolutionize the decision-making process.
UR - http://www.scopus.com/inward/record.url?scp=85134560023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134560023&partnerID=8YFLogxK
U2 - 10.5152/tud.2022.22028
DO - 10.5152/tud.2022.22028
M3 - Review article
AN - SCOPUS:85134560023
SN - 2149-3235
VL - 48
SP - 262
EP - 267
JO - Turkish Journal of Urology
JF - Turkish Journal of Urology
IS - 4
ER -